|

Cadonilimab (AK104) Clinical Trials

5 actively recruiting trials

Pipeline

Phase 2: 3Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Xin-Hua Xu1
  • Hubei Cancer Hospital1
  • Guangzhou Medical University1
  • Chongqing University Cancer Hospital1
  • Akeso1

Indications

  • Cancer5
  • Lung Cancer2
  • NSCLC (Non-small Cell Lung Cancer)1
  • Locally Advanced Cervical Cancer1
  • Breast Cancer1

Other5 trials

A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy
Phase 2
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
Phase 3
Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis
Phase 1/2
SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)
Phase 2
Study Of Cadonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.